Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avacta Group plc ( (GB:AVCT) ) has provided an announcement.
Avacta Group PLC announced it will release its audited preliminary results for the fiscal year ending December 31, 2024, on May 29, 2025. The announcement will be accompanied by a live investor presentation by CEO Christina Coughlin and CFO Brian Hahn, accessible through the Investor Meet Company platform. This event is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing next-generation peptide drug conjugates (PDC) for cancer treatment. Their proprietary pre|CISION® platform targets tumor-specific proteases to deliver potent anti-tumor payloads directly to tumors, minimizing systemic exposure and toxicity.
Average Trading Volume: 1,934,053
Technical Sentiment Signal: Sell
Current Market Cap: £130.4M
See more data about AVCT stock on TipRanks’ Stock Analysis page.